Cardiovascular Medications in Pregnancy

Clinical Pharmacology During Pregnancy

Volumn , Issue , 2013, Pages 275-294

  Easterling, Thomas R ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882650201     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-386007-1.00017-9     Document Type: Chapter

References (35)

1. Easterling T.R., Benedetti T.J., Schmucker B.C., Millard S.P. Maternal hemodynamics in normal and preeclamptic pregnancies: a longitudinal study. Obstet Gynecol 1990, 76:1061-1069.
2. Bosio P.M., McKenna P.J., Conroy R., O'Herlihy C. Maternal central hemodynamics in hypertensive disorders of pregnancy. Obstet Gynecol 1999, 94:978-984.
3. Robson S., Dunlop W., Boys R., Hunter S. Cardiac output during labour. BMJ 1987, 295:1169-1172.
4. Robson S., Boys R., Hunter S., Dunlop W. Maternal hemodynamics after normal delivery and delivery complicated by postpartum hemorrhage. Obstet Gynecol 1989, 74:234-239.
5. Clark S., Phelan J., Greenspoon J., et al. Labor and delivery in the presence of mitral stenosis: central hemodynamic observations. Am J Obstet Gynecol 1985, 152:384.
6. Davison J., Lindheimer M. Volume homeostasis and osmoregulation in human pregnancy. Baillieres Clin Endocrinol Metab 1989, 3:451-472.
7. Altman D., Carroli G., Duley L., Farrell B., Moodley J., Neilson J., et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002, 359:1877-1890.
8. Magee L.A., Duley L. Oral beta-blockers for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2003, CD002863.
9. Carr D.B., Koontz G.L., Gardella C., Holing E.V., Brateng D.A., Brown Z.A., et al. Diabetic nephropathy in pregnancy: suboptimal hypertensive control associated with preterm delivery. Am J Hypertens 2006, 26:5005-5012.
10. von Dadelszen P., Ornstein M.P., Bull S.B., Logan A.G., Koren G., Magee L.A. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet 2000, 35587-35589.
11. Easterling T.R., Benedetti T.J., Carlson K.L., Brateng D.A., Wilson, Schmucker B.C. The effect of maternal hemodynamics on fetal growth in hypertensive pregnancies. Am J Obstet Gynecol 1991, 165:902-906.
12. Easterling T.R., Carr D.B., Brateng D., Diederichs C., Schmucker B. Treatment of hypertension in pregnancy: effect of atenolol on maternal disease, preterm delivery, and fetal growth. Obstet Gynecol 2001, 98:427-433.
13. al Kasab S.M., Sabag T., al Zaibag M., Awaad M., al Bitar I., Halim M.A., et al. Beta-adrenergic receptor blockade in the management of pregnant women with mitral stenosis. Am J Obstet Gynecol 1990, 16:337-340.
14. Easterling T.R., Benedetti T.J., Schmucker B.C., Carlson K.L. Antihypertensive therapy in pregnancy directed by noninvasive hemodynamic monitoring. Am J Perinat 1989, 6:86-89.
15. Easterling T.R., Carr D.B., Davis C., Diedrichs C., Brateng D.A., Schmucker B. Low dose, short acting angiotensin converting enzyme inhibitors: use in pregnancy. Obstet Gynecol 2000, 96:956-961.
16. Scardo J.A., Vermillion S.T., Hogg B.B., Newman R.B. Hemodynamic effects of oral nifedipine in preeclamptic hypertensive emergencies. Am J Obstet Gynecol 1996, 175:336-338.
17. Serra-Serra V., Kyle P.M., Chandran R., Redman C.W. The effect of nifedipine and methyldopa on maternal cerebral circulation. Br J Obstet Gynecol 1997, 104:532-537.
18. Carr D.B., Gavrila D., Brateng D., Easterling T.R. Maternal hemodynamic changes associated with furosemide treatment. Hypertens Pregnancy 2007, 26:173-178.
19. Rothberger S., Carr D., Brateng D., Hebert M., Easterling T.R. Pharmacodynamics of clonidine therapy in pregnancy: a heterogeneous maternal response impacts fetal growth. Am J Hypertens 2010, 231:234-240.
20. Carvalho T.M., Cavalli R.C., Cunha S.P., Baraldi C.O., Marques M.P., Antunes N.J., et al. Influence of gestational diabetes mellitus on the stereoselective kinetic disposition and metabolism of labetalol in hypertensive patients. Eur J Clin Pharmacol 2011, 67:55-61.
21. MacCarthy E.P., Bloomfield S.S. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. Pharmacotherapy 1983, 3:193-219.
22. Butters L., Kennedy S., Rubin P.C. Atenolol in essential hypertension during pregnancy. BMJ 1990, 301(6752):587-589.
23. Easterling T.R., Brateng D., Schmucker B., Brown Z., Millard S.P. Prevention of preeclampsia: a randomized trial of atenolol in hyperdynamic patients prior to the onset of hypertension. Obstet Gynecol 1999, 93(5):725-733.
24. Easterling T.R., Carr D.B., Davis C., Diedrichs C., Brateng D.A., Schmucker B. Low dose, short acting angiotensin converting enzyme inhibitors: use in pregnancy. Obstet Gynecol 2000, 96:956-961.
25. Cooper W.O., Hernandez-Diaz S., Arbogast P.G., Dudley J.A., Dyer S., Gideon P.S., et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006, 354:2443-2451.
26. Lennestål R., Olaussonb P.O., Källén B. Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. Eur J Clin Pharmacol 2009, 65:615-625.
27. Hebert M., Easterling T., Kirby B., Carr D., Buchanan M., Rutherford T., et al. Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington Specialized Center of Research Study. Clin Pharmacol Ther 2008, 84:248-253.
28. Hebert M.F., Carr D.B., Anderson G.D., Blough D., Green G.E., Brateng D.A., et al. Pharmacokinetics and pharmacodynamics of atenolol during pregnancy and postpartum. J Clin Pharmacol 2005, 45:25-33.
29. Eyal S., Kim J.D., Anderson G.D., Buchanan M.L., Brateng D.A., Carr D., et al. Atenolol pharmacokinetics and excretion in breast milk during the first 6 to 8 months postpartum. J Clin Pharmacol 2010, 50:1301-1309.
30. Schimmel M.S., Eidelman A.I., Wilschanski M.A., Shaw D., Ogilvie R.J., Koren G. Toxic effects of atenolol consumed during breast feeding. J Pediatr 1989, 114476-114478.
31. Tracy T.S., Venkataramanan R., Glover D.D., Caritis S.N. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet Gynecol 2005, 192:633-639.
32. Yep T, Eyal S, Easterling TR, Shen DD, Kelly EJ, Hankins GDV, et al. The pharmacokinetics of metoprolol during pregnancy. Abstract 2011 Annual Meeting American College of Clinical Pharmacology, Pittsburgh, PA, October 16-19.
33. Rogers R.C., Sibai B.M., Whybrew W.D. Labetalol pharmacokinetics in pregnancy-induced hypertension. Am J Obstet Gynecol 1990, 162:362-366.
34. Prevost R.R., Aki S.A., Whybrew W.D., Sibai B.M. Oral nifedipine pharmacokinetics in pregnancy-induced hypertension. Pharmacotherapy 1991, 12:174-177.
35. Buchanan M.L., Easterling T.R., Carr D.B., Shen D.D., Risler L.J., Nelson W.L., et al. Clonidine pharmacokinetics in pregnancy. Drug Metab Dispos 2009, 37:702-705.